TICKERNERD
Menu
TMDXTMDXHealthcare · Medical Devices

TMDX Stock Forecast: TransMedics Group, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$87
+3.19% on the day

The 12 Wall Street analysts covering TransMedics Group, Inc. hold a median 12-month price target of $98 — +12.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 2 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$2.9B
Ticker Nerd rank
32 / 100
Median analyst target
$98
Analysts covering
12
Revenue$189.9M+20.7% y/y
Operating income$23.7M
Net income$14.7M
Free cash flow$10.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.2%
1M
+6.7%
YTD
−28.5%
1Y
−18.7%
From 52W high
−42.2%
From 52W low
+40.2%
$62
$150
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TransMedics Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
32 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
85
Value
71
Growth
63
Volatility
63
Revisions
40
Size
31
Momentum
22
Accruals
19
Issuance
18

Quality (85): The business earns solid, repeatable profits on what it owns.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TMDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26TMDXHigh $125Median $98Low $65

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
8 Buy4 Hold0 Sell
Low $65Median $98High $125

The green dot is the last close — the median target sits +12.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
5 Aug 2026Piper SandlerReiteratesOverweight$120 → $100
5 Aug 2026UBSMaintainsNeutral$80 → $77
3 Aug 2026NeedhamMaintainsBuy$142 → $106
28 July 2026UBSInitiatesNeutral—
6 July 2026Evercore ISI GroupMaintainsOutperform$100 → $90
6 July 2026Evercore ISI GroupMaintainsOutperform—
1 July 2026TD CowenReiteratesBuy$120
1 July 2026TD CowenReiteratesBuy—
30 June 2026Canaccord GenuityMaintainsBuy$124
30 June 2026Canaccord GenuityMaintainsBuy—
18 June 2026StifelMaintainsHold—
26 May 2026StifelMaintainsHold—
6 May 2026Canaccord GenuityMaintainsBuy—
6 May 2026NeedhamMaintainsBuy—
6 May 2026Piper SandlerMaintainsOverweight—
6 May 2026StifelMaintainsHold—
6 May 2026TD CowenMaintainsBuy—
6 Apr 2026Evercore ISI GroupMaintainsOutperform—
9 Mar 2026StifelMaintainsHold—
25 Feb 2026Evercore ISI GroupMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMDX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TMDX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, TransMedics Group, Inc. returned −18.7% against +21.4% for the S&P 500, dividends included.

TMDX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Oct 25Jan 26Apr 26Jul 26TMDXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TMDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−28.0%
Analysts raising
0
Analysts cutting
7
Fundamentals

TransMedics Group, Inc. (TMDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.3×

Cheaper than 36% of US stocks

Price / sales
4.3×

Cheaper than 29% of US stocks

Price / book
5.5×

Cheaper than 19% of US stocks

EV / EBITDA
28.1×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
20.7%

Higher than 70% of US stocks

Earnings growth (YoY)
−57.9%

Higher than 8% of US stocks

Gross margin
59.6%

Higher than 73% of US stocks

Operating margin
12.5%

Higher than 68% of US stocks

Net margin
22.7%

Higher than 84% of US stocks

Returns & dividend
Return on equity
36.3%

Higher than 90% of US stocks

Return on assets
4.3%

Higher than 73% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TransMedics Group, Inc. (TMDX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TransMedics Group, Inc. has a market value of $2.9B and an enterprise value of $3.2B.

  • Revenue in the twelve months to 30 June 2026: $668.5M. The latest quarter grew 20.7% year on year.

  • Net income over the same four quarters: $151.7M, a 22.7% net margin.

  • Diluted earnings per share, trailing twelve months: $3.89.

  • Free cash flow in the twelve months to 30 June 2026: $79.0M.

  • Shares outstanding: 34.6M.

  • Trailing P/E: 21.3×; forward P/E: 35.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • TransMedics Group, Inc. employs 898 people — $744K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 2 Sept 2026

Data provided by Twelve Data

Peers

TMDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TMDXTransMedics Group, Inc.$2.9B
32
NEOGNeogen Corp.$2.6B
95
AXGNAxoGen, Inc.$2.6B
77
UFPTUFP Technologies, Inc.$2.3B
78
ESTAEstablishment Labs Holdings, Inc.$2.2B
76
IRTCiRhythm Holdings, Inc.$4.0B
77
ALMRAlamar Biosciences, Inc. (California)$2.1B
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TransMedics Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TMDX news & analysis

Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?

Zacks Investment Research · 3 Sept 2026neutral

Zacks Investment Research notes that TransMedics' rapid revenue growth and lower valuation are being weighed against rising margin pressure stemming from heavy investment, which increases execution risks for the company.

Why it matters — A TMDX watcher would care because the balance between growth momentum and mounting margin pressure highlights execution risk that could influence the stock's longer-term prospects.

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?

Zacks Investment Research · 3 Sept 2026positive

TransMedics reported earnings 30 days ago, and its stock has risen 10.2% since that report. The item discusses the stock's performance following the recent earnings announcement.

Why it matters — A TMDX watcher would care because the stock has gained 10.2% in the month since the company's last earnings report.

TransMedics to Present at Upcoming September Investor Conferences

PRNewsWire · 31 Aug 2026neutral

TransMedics Group, Inc. announced it will participate in two upcoming investor conferences in September. The company, which develops technology for organ transplant therapy, will present at these events for investors and analysts.

Why it matters — A TMDX watcher would care because investor conference presentations provide opportunities for management to update the investment community on the company's business and strategy.

Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

PRNewsWire · 25 Aug 2026negative

A law firm has issued a notice encouraging TransMedics Group, Inc. shareholders to contact them regarding potential breaches of fiduciary duties by company insiders. The firm states it would handle any matter on a contingency fee basis with no out-of-pocket costs to shareholders.

Why it matters — TMDX watchers would want to monitor this because allegations of insider fiduciary breaches could signal shareholder-rights issues legal scrutiny of the company.

TransMedics Targets $2B Opportunity With Kidney Push, European Expansion

MarketBeat · 18 Aug 2026neutral

TransMedics Group outlined its growth strategy at Canaccord Genuity's 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology, and broader adoption in heart and lung transplantation.

Why it matters — The announcement signals where TransMedics is directing its resources beyond its core heart and lung organ-preservation business, which could shape its future growth trajectory.

FAQ

Frequently asked questions about TMDX stock

What is the TMDX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering TransMedics Group, Inc. have a median 12-month price target of $98, with estimates ranging from $65 to $125. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMDX stock a buy right now?

Of the 12 analysts covering TransMedics Group, Inc., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransMedics Group, Inc. 32 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMDX?

As at 2 Sept 2026, TransMedics Group, Inc. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (85 of 100).

Will TMDX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +12.1% from the last close, and Ticker Nerd's factor model ranks TransMedics Group, Inc. 32 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMDX stock forecast for 2030?

No analyst covering TransMedics Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $125 over the next 12 months.

How has TMDX stock performed over the past year?

TransMedics Group, Inc. returned -18.7% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TransMedics Group, Inc. do?

TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy.

What is the latest news on TMDX?

The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?". Zacks Investment Research notes that TransMedics' rapid revenue growth and lower valuation are being weighed against rising margin pressure stemming from heavy investment, which increases execution risks for the company.

Company

About TransMedics Group, Inc.

TransMedics Group, Inc. is a commercial-stage medical technology company focused on organ transplant therapy. The company develops and commercializes the Organ Care System (OCS), a platform designed to preserve, monitor, and assess donor organs outside the human body in conditions that more closely resemble a living environment. Its current portfolio supports heart, lung, and liver transplantation, helping transplant teams manage donor organs more effectively than traditional cold storage methods. TransMedics also provides related disposables and service offerings that support organ transport, preservation, and clinical workflow in the transplant process. Headquartered in Andover, Massachusetts, TransMedics Group, Inc. serves a specialized role in healthcare by addressing the needs of patients with end-stage organ failure and supporting hospitals, transplant centers, and organ recovery organizations across its markets.

CEO Dr. Waleed H. Hassanein M.D. · 898 employees · United States · https://www.transmedics.com